Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Relacorilant: First Approval.

Drugs·2026

Same author

Rovadicitinib: First Approval.

Drugs·2026

Same author

Sonrotoclax: First Approval.

Drugs·2026

Same author

Copper Histidinate: Pediatric First Approval.

Paediatric drugs·2026

Same author

Correction: Avutometinib and Defactinib: First Approval.

Drugs·2026

Same author

Lerodalcibep: First Approval.

Drugs·2026

Same journal

Advances in Gene and Cellular Therapy in Friedreich Ataxia.

Molecular diagnosis & therapy·2026

Same journal

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.

Molecular diagnosis & therapy·2026

Same journal

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026

Same journal

Genetics of Cerebrotendinous Xanthomatosis.

Molecular diagnosis & therapy·2026

Same journal

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026

Same journal

LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.

Molecular diagnosis & therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Etuvetidigene Autotemcel: First Approval.

Hannah A Blair¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. mdt@adis.com.

Molecular Diagnosis & Therapy

|March 26, 2026

Summary

This summary is machine-generated.

Etuvetidigene autotemcel (WASKYRA™) is a novel gene therapy for Wiskott-Aldrich syndrome (WAS). It received FDA and EMA approval in late 2025/early 2026 for patients lacking a matched donor.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 27, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Hematology
Gene Therapy
Immunology

Background:

Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency.
Current treatments include hematopoietic stem cell transplantation (HSCT), which requires a matched donor.
Gene therapy offers a potential alternative for patients without a suitable donor.

Purpose of the Study:

To summarize the development milestones of etuvetidigene autotemcel.
To highlight its recent regulatory approvals for WAS treatment.

Main Methods:

Autologous hematopoietic stem cell (HSC) gene therapy approach.
Development by Fondazione Telethon.
Regulatory review processes in the USA and EU.

Main Results:

Etuvetidigene autotemcel (WASKYRA™) development milestones leading to regulatory approval.
FDA approval in December 2025 for WAS patients aged 6 months and older.
EMA approval in January 2026 for the same indication.

Conclusions:

Etuvetidigene autotemcel represents a significant advancement in WAS treatment.
The therapy provides a new option for patients ineligible for traditional HSCT.
Successful development and approval mark a milestone in rare disease gene therapy.